Over recent years, we have seen an increasing number of financial schemes being offered to NHS Trusts.
Now that the commissioner model of the NHS has been fully implemented, pharmaceutical manufacturers are looking for opportunities to emulate the secondary care model, paying retrospective discounts to commissioners based on sales into the community.
This is also an area that GPs are familiar with and increasingly something commissioners are considering.
Whilst discounts to primary care commissioners could provide significant efficiency savings, if correctly and transparently governed, there is a risk of perverse incentives altering local prescribing adversely.
In response to these risks, the Pharmaceutical Industry Scheme Governance Review Board has been established to address these risks.
Delivered as part of what we deliver to those commissioners who subscribers, the Board is offering comprehensive governance to assess whether schemes offered locally are clinically and financially appropriate.
Please find more information about primary care rebate schemes here.
EoE PIS Governance Review Board Operating Model
Primary care rebate schemes webinar - October 2017
On 30th October PrescQIPP hosted a webinar on primary care rebate scheme (PCRS) governance systems in the United Kingdom, covering the PrescQIPP Pharmaceutical Industry Scheme Governance Review Board.
The session was chaired by Kevan Wind, and was a general educational session for stakeholders, including the pharmaceutical industry to help explain our assessment process.